Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Alaunos Therapeutics, Inc.TCRT · Entity 8339 | Director | October 06, 2026 | October 08, 2026 |
| Mountain Lake Acquisition Corp. IIMLAA · Entity 9297 | Director | January 26, 2026 | January 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Alaunos Therapeutics, Inc.
Report date October 06, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 70,311 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Grant · Acquired 22,669 · Balance 70,311 F1: Represents shares of common stock issued in lieu of board fees. |
| Common StockSEC Table I · non-derivative | Indirectby Reporter's children | 2,100 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,100 |
| Common StockSEC Table I · non-derivative | IndirectBy Brushwood LLC | 13,503 |
Reported balance
Holding disclosure · report date 2026-10-06 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 13,503 F2: The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued in lieu of board fees.
F2: The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC.
Mountain Lake Acquisition Corp. II
Report date January 26, 2026 · Filed January 27, 2026
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mountain Lake Acquisition Corp.
Report date June 11, 2026 · Filed June 15, 2026
Section 16 reporting ended · disclosed 2026-06-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A ordinary shares, par value $0.0001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 1
1 source rowRow 1 · 2026-06-11 · Disposition to issuer · Disposed 478,010 · Balance 0 F2: In connection with the SPAC Merger (as defined in the Business Combination Agreement), an aggregate of 478,010 Class A ordinary shares held by the Reporting Person were exchanged into an equal number of shares of Class A common stock, par value $0.01 per share, of Pubco. Following such transaction, the Reporting Person owns zero Class A ordinary shares. |
| Class B ordinary shares, par value $0.0001 per shareSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-11 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-11 · Exercise / conversion · Disposed 478,010 · Balance 0 F1: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F3: On June 11, 2026, in connection with the consummation of the transactions contemplated by the Business Combination Agreement dated October 1, 2025 (as amended on January 13, 2026 and March 17, 2026, the "Business Combination Agreement" and the transactions contemplated thereto, the "Business Combination"), by and among the Issuer, Avalanche Treasury Corporation, a Delaware corporation ("Pubco") and the other parties thereto, 478,010 Class B ordinary shares were converted into an aggregate of 478,010 Class A ordinary shares (the "Class B Conversion"). Following the Class B Conversion, the Reporting Person owns zero Class B ordinary shares. |
Filing footnotes · ownership attribution and instrument terms
F1: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments.
F2: In connection with the SPAC Merger (as defined in the Business Combination Agreement), an aggregate of 478,010 Class A ordinary shares held by the Reporting Person were exchanged into an equal number of shares of Class A common stock, par value $0.01 per share, of Pubco. Following such transaction, the Reporting Person owns zero Class A ordinary shares.
F3: On June 11, 2026, in connection with the consummation of the transactions contemplated by the Business Combination Agreement dated October 1, 2025 (as amended on January 13, 2026 and March 17, 2026, the "Business Combination Agreement" and the transactions contemplated thereto, the "Business Combination"), by and among the Issuer, Avalanche Treasury Corporation, a Delaware corporation ("Pubco") and the other parties thereto, 478,010 Class B ordinary shares were converted into an aggregate of 478,010 Class A ordinary shares (the "Class B Conversion"). Following the Class B Conversion, the Reporting Person owns zero Class B ordinary shares.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 8, 2026 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 22,669 | $0.74 | $16,874.80 |
DisclosureSEC source: 0001193125-26-417971 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,311 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:15 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 8,789 | $1.92 | $16,874.88 |
DisclosureSEC source: 0001193125-26-318100 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,642 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:15 UTC | Mountain Lake Acquisition Corp. MLAC · Entity 38249 | Exercise / conversionClass B ordinary shares, par value $0.0001 per share · Derivative | 478,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-068799 · ownership.xml · derivative · entry 2 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A ordinary shares · 478,010 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F3 · derivative.exercise_price: On June 11, 2026, in connection with the consummation of the transactions contemplated by the Business Combination Agreement dated October 1, 2025 (as amended on January 13, 2026 and March 17, 2026, the "Business Combination Agreement" and the transactions contemplated thereto, the "Business Combination"), by and among the Issuer, Avalanche Treasury Corporation, a Delaware corporation ("Pubco") and the other parties thereto, 478,010 Class B ordinary shares were converted into an aggregate of 478,010 Class A ordinary shares (the "Class B Conversion"). Following the Class B Conversion, the Reporting Person owns zero Class B ordinary shares. F1 · kind: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F3 · kind: On June 11, 2026, in connection with the consummation of the transactions contemplated by the Business Combination Agreement dated October 1, 2025 (as amended on January 13, 2026 and March 17, 2026, the "Business Combination Agreement" and the transactions contemplated thereto, the "Business Combination"), by and among the Issuer, Avalanche Treasury Corporation, a Delaware corporation ("Pubco") and the other parties thereto, 478,010 Class B ordinary shares were converted into an aggregate of 478,010 Class A ordinary shares (the "Class B Conversion"). Following the Class B Conversion, the Reporting Person owns zero Class B ordinary shares. F1 · price: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F3 · price: On June 11, 2026, in connection with the consummation of the transactions contemplated by the Business Combination Agreement dated October 1, 2025 (as amended on January 13, 2026 and March 17, 2026, the "Business Combination Agreement" and the transactions contemplated thereto, the "Business Combination"), by and among the Issuer, Avalanche Treasury Corporation, a Delaware corporation ("Pubco") and the other parties thereto, 478,010 Class B ordinary shares were converted into an aggregate of 478,010 Class A ordinary shares (the "Class B Conversion"). Following the Class B Conversion, the Reporting Person owns zero Class B ordinary shares. F1 · derivative.exercise_date: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F3 · derivative.exercise_date: On June 11, 2026, in connection with the consummation of the transactions contemplated by the Business Combination Agreement dated October 1, 2025 (as amended on January 13, 2026 and March 17, 2026, the "Business Combination Agreement" and the transactions contemplated thereto, the "Business Combination"), by and among the Issuer, Avalanche Treasury Corporation, a Delaware corporation ("Pubco") and the other parties thereto, 478,010 Class B ordinary shares were converted into an aggregate of 478,010 Class A ordinary shares (the "Class B Conversion"). Following the Class B Conversion, the Reporting Person owns zero Class B ordinary shares. F1 · derivative.expiration_date: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F3 · derivative.expiration_date: On June 11, 2026, in connection with the consummation of the transactions contemplated by the Business Combination Agreement dated October 1, 2025 (as amended on January 13, 2026 and March 17, 2026, the "Business Combination Agreement" and the transactions contemplated thereto, the "Business Combination"), by and among the Issuer, Avalanche Treasury Corporation, a Delaware corporation ("Pubco") and the other parties thereto, 478,010 Class B ordinary shares were converted into an aggregate of 478,010 Class A ordinary shares (the "Class B Conversion"). Following the Class B Conversion, the Reporting Person owns zero Class B ordinary shares. Read SEC document |
| June 11, 2026 Filed Jun 15, 2026 20:15 UTC | Mountain Lake Acquisition Corp. MLAC · Entity 38249 | Disposition to issuerClass A ordinary shares, par value $0.0001 per share | 478,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-068799 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · kind: In connection with the SPAC Merger (as defined in the Business Combination Agreement), an aggregate of 478,010 Class A ordinary shares held by the Reporting Person were exchanged into an equal number of shares of Class A common stock, par value $0.01 per share, of Pubco. Following such transaction, the Reporting Person owns zero Class A ordinary shares. F2 · price: In connection with the SPAC Merger (as defined in the Business Combination Agreement), an aggregate of 478,010 Class A ordinary shares held by the Reporting Person were exchanged into an equal number of shares of Class A common stock, par value $0.01 per share, of Pubco. Following such transaction, the Reporting Person owns zero Class A ordinary shares. Read SEC document |
| June 01, 2026 Filed Jun 5, 2026 00:45 UTC | Mountain Lake Acquisition Corp. MLAC · Entity 38249 | OtherClass B ordinary shares, par value $0.0001 per share · Derivative | 478,010 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-065442 · ownership.xml · derivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 478,010 Underlying: Class A ordinary shares · 478,010 shares Expires not disclosed F1 · derivative.exercise_price: Represents Class B ordinary shares of the Issuer received in a pro rata distribution of assets by Mountain Lake Acquisition Sponsor LLC (the "Sponsor") to its constituent members (the "Sponsor Distribution"). No consideration was paid in connection with the transaction reported herein. F2 · derivative.exercise_price: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F1 · kind: Represents Class B ordinary shares of the Issuer received in a pro rata distribution of assets by Mountain Lake Acquisition Sponsor LLC (the "Sponsor") to its constituent members (the "Sponsor Distribution"). No consideration was paid in connection with the transaction reported herein. F2 · price: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F2 · derivative.exercise_date: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F2 · derivative.expiration_date: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the Class B ordinary shares will automatically convert into Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. Read SEC document |
| April 29, 2026 Filed May 1, 2026 20:30 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 6,515 | $2.59 | $16,873.85 |
DisclosureSEC source: 0001193125-26-201557 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,853 Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 21:15 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 5,839 | $2.89 | $16,874.71 |
DisclosureSEC source: 0001193125-26-014115 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,338 Read SEC document |
| November 21, 2025 Filed Nov 27, 2025 02:32 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 5,340 | $3.16 | $16,874.40 |
DisclosureSEC source: 0001193125-25-301033 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,499 F1 · shares: Represents shares of common stock issued in lieu of board fees. Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 23:11 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 6,400 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0000950170-25-094386 · ownership.xml · derivative · entry 4 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,400 Underlying: Common Stock · 6,400 shares Expires 2035-07-03 F3 · derivative.exercise_date: One-twelfth of the Option vests each month on the monthly anniversary of July 3, 2025, with any amount that remains unvested on the date immediately preceding the Company's 2026 annual general meeting of stockholders vesting thereon. Read SEC document |
| July 03, 2025 Filed Jul 7, 2025 23:11 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 3,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-094386 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,159 F1 · shares: Represents a grant of restricted stock units (RSUs) which immediately vested upon grant. After the reported acquisition of the RSUs, the reporting person owned in aggregate 21,159 shares of common stock (17,759 previously owned shares, plus the instant grant of 3,400 RSUs). Read SEC document |
| June 24, 2025 Filed Jun 27, 2025 01:22 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | PurchaseSeries A-2 Convertible Preferred Stock · Derivative | 250 | $4.49 Strike: $4.49 | $1,122.50 |
DisclosureSEC source: 0000950170-25-090589 · ownership.xml · derivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250 Underlying: Common Stock · 55,679.29 shares Expires not disclosed F1 · derivative.expiration_date: The preferred stock is perpetual and therefore has no expiration date. Read SEC document |
| April 13, 2025 Filed Apr 16, 2025 00:26 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 17,465 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-054429 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,359 F1 · shares: Represents a grant of restricted stock units which immediately vested upon grant. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:34 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | SaleCommon Stock | 818 | $2.00 | $1,636.00 |
DisclosureSEC source: 0000950170-25-001257 · ownership.xml · nonDerivative · entry 2 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,894 Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 21:34 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | SaleCommon Stock | 2,182 | $2.01 | $4,385.82 |
DisclosureSEC source: 0000950170-25-001257 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,712 Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 01:23 UTC | Mountain Lake Acquisition Corp. MLAC · Entity 38249 | PurchaseRights to receive Class A Ordinary Shares · Derivative | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-109470 · ownership.xml · derivative · entry 4 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 25,000 Underlying: Class A Ordinary Share, par value $0.0001 per share · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: The private units were purchased at $10.00 per unit. F1 · shares: Reflects private units owned by Mountain Lake Acquisition Sponsor LLC, the Issuer's sponsor (the "Sponsor"), in which the reporting person has a pecuniary interest. The private units consist of Class A ordinary shares and rights. F2 · price: The private units were purchased at $10.00 per unit. F7 · price: The rights convert automatically into Class A ordinary shares at the completion of the Issuer's initial business combination. F7 · derivative.exercise_date: The rights convert automatically into Class A ordinary shares at the completion of the Issuer's initial business combination. F7 · derivative.expiration_date: The rights convert automatically into Class A ordinary shares at the completion of the Issuer's initial business combination. F1 · ownership.nature: Reflects private units owned by Mountain Lake Acquisition Sponsor LLC, the Issuer's sponsor (the "Sponsor"), in which the reporting person has a pecuniary interest. The private units consist of Class A ordinary shares and rights. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 01:23 UTC | Mountain Lake Acquisition Corp. MLAC · Entity 38249 | Disposition to issuerClass B ordinary shares, par value $0.0001 per share · Derivative | 65,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-109470 · ownership.xml · derivative · entry 3 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,286,541 Underlying: Class A ordinary shares · 65,242 shares Expires not disclosed F3 · derivative.exercise_price: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the shares of Class B ordinary shares will automatically convert into shares of Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F5 · price: Reflects the forfeiture of shares because the Issuer's over-allotment option was only partially exercised by the underwriters. F3 · derivative.exercise_date: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the shares of Class B ordinary shares will automatically convert into shares of Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F3 · derivative.expiration_date: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the shares of Class B ordinary shares will automatically convert into shares of Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F6 · ownership.nature: Reflects the Class B ordinary shares owned by the Sponsor in which the reporting person has a pecuniary interest. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 01:23 UTC | Mountain Lake Acquisition Corp. MLAC · Entity 38249 | PurchaseClass A Ordinary Share, par value $0.0001 per share | 25,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-109470 · ownership.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 25,000 F1 · shares: Reflects private units owned by Mountain Lake Acquisition Sponsor LLC, the Issuer's sponsor (the "Sponsor"), in which the reporting person has a pecuniary interest. The private units consist of Class A ordinary shares and rights. F2 · price: The private units were purchased at $10.00 per unit. F1 · ownership.nature: Reflects private units owned by Mountain Lake Acquisition Sponsor LLC, the Issuer's sponsor (the "Sponsor"), in which the reporting person has a pecuniary interest. The private units consist of Class A ordinary shares and rights. Read SEC document |
| December 12, 2024 Filed Dec 17, 2024 01:23 UTC | Mountain Lake Acquisition Corp. MLAC · Entity 38249 | GrantClass B ordinary shares, par value $0.0001 per share · Derivative | 65,242 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-24-109470 · ownership.xml · derivative · entry 2 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 1,351,783 Underlying: Class A ordinary shares · 65,242 shares Expires not disclosed F3 · derivative.exercise_price: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the shares of Class B ordinary shares will automatically convert into shares of Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F4 · price: Reflects the issuance of bonus shares on December 12, 2024 in connection with the upsize of the Issuer's initial public offering. F3 · derivative.exercise_date: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the shares of Class B ordinary shares will automatically convert into shares of Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F3 · derivative.expiration_date: As described in the registration statement on Form S-1 (File No. 333-281410) of the Issuer under the heading "Description of Securities--Founder Shares," the shares of Class B ordinary shares will automatically convert into shares of Class A ordinary shares at the time of the Issuer's initial business combination, or at any time prior to the Issuer's initial business combination, at the option of the holder, on a one-for-one basis, subject to certain adjustments. F6 · ownership.nature: Reflects the Class B ordinary shares owned by the Sponsor in which the reporting person has a pecuniary interest. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 21:00 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 12,800 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-071400 · ownership.xml · derivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,800 Underlying: Common Stock · 12,800 shares Expires 2034-06-05 F1 · derivative.exercise_date: One-twelfth of the Option vests each month on the monthly anniversary of June 6, 2024, with any amount that remains unvested on the date immediately preceding the Company's 2025 annual general meeting of stockholders vesting thereon. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 21:17 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0000899243-23-014913 · doc4.xml · derivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-06-05 F1 · derivative.exercise_date: One-twelfth of the shares underlying the option vest in equal monthly installments measured from June 6, 2023, with the first vesting occurring on July 6, 2023, subject to the Reporting Person's continued service through each such date. Read SEC document |
| November 29, 2022 Filed Dec 1, 2022 21:05 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | PurchaseCommon Stock | 1,250,000 | $0.65 | $812,500.00 |
DisclosureSEC source: 0000899243-22-037274 · doc4.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Brushwood LLC Disclosed balance after: 1,250,000 F2 · price: The shares were purchased in a registered underwritten offering on November 29, 2022. F1 · balance_after: The shares are directly held by Brushwood LLC. The Reporting Person is the Manager of Brushwood LLC. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:31 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantEmployee Stock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0000899243-22-023985 · doc4.xml · derivative · entry 6 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments beginning on July 13, 2022. Read SEC document |
| June 22, 2022 Filed Jun 24, 2022 20:31 UTC | Alaunos Therapeutics, Inc. TCRT · Entity 8339 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023985 · doc4.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 745,321 Read SEC document |
| September 29, 2021 Filed Oct 4, 2021 22:11 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | PurchaseCommon Stock | 100,000 | $1.91 | $191,000.00 |
DisclosureSEC source: 0001209191-21-059131 · doc4.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 705,321 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90 to $1.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:26 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030745 · doc4.xml · derivative · entry 7 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2031-03-03 F3 · derivative.exercise_date: 1/36th of the shares underlying this option will vest in equal monthly installments commencing one month after 12/15/2020. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:26 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantStock Option (right to buy) · Derivative | 31,250 | $0.00 Strike: $4.31 | $0.00 |
DisclosureSEC source: 0001209191-21-030745 · doc4.xml · derivative · entry 6 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 31,250 shares Expires 2031-03-03 F2 · derivative.exercise_date: 1/3rd of the shares underlying this option will vest on 4/4/2021, 5/4/2021 and 5/19/2021. Read SEC document |
| March 04, 2021 Filed May 6, 2021 23:26 UTC | Alaunos Therapeutics, Inc. ZIOP · Entity 8339 | GrantCommon Stock | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030745 · doc4.xml · nonDerivative · entry 1 Vieser Jaime · CIK 0001846045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 605,321 F1 · shares: The shares will vest on 5/19/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.